Spatial proteomic analysis of a lung cancer model reveals regulatory T cells attenuate KRAS-G12C inhibitor-induced immune responses

Megan Cole,Panayiotis Anastasiou,Claudia Lee,Chris Moore,Edurne Mugarza,Martin Jones,Karishma Valand,Sareena Rana,Emma Colliver,Mihaela Angelova,Katey S.S. Enfield,Alastair Magness,Asher Mullokandov,Gavin Kelly,Tanja D. de Gruijl,Miriam Molina-Arcas,Charles Swanton,Julian Downward,Febe van Maldegem

DOI: https://doi.org/10.1101/2024.04.11.588725

2024-04-13

Abstract:We recently showed that lung tumor specific KRAS-G12C inhibition causes remodelling of the tumor immune microenvironment from cold to hot. As a result, KRAS-G12C inhibition is able to synergise with anti-PD-1 treatment, but only in tumor models that were already moderately responsive to immune checkpoint blockade at baseline. To investigate mechanisms that restrain immunotherapy sensitivity in non-responsive tumors, we used multiplex imaging mass cytometry to explore spatial patterns in the tumor microenvironment of the highly immune evasive KRAS mutant murine Lewis Lung Cancer model. Clustering of close neighbour information per cell allowed characterisation of spatial patterns or ‘communities’ in the tissue. We identified a community harbouring features of localised T-cell activation, where CD4 and CD8 T cells and dendritic cells were gathered together. KRAS-G12C inhibition led to increased expression of PD-1 on T cells, CXCL9 expression by dendritic cells, together with increased proliferation and potential cytotoxicity of CD8 T cells, indicating an effector response. However, we also observed a high incidence of regulatory T cells (Tregs) within this community, which had frequent contact with effector T cells, suggesting that Tregs may be able to dampen anti-tumoral immune responses following KRAS-G12C inhibition. Similar communities were detected in human lung adenocarcinoma clinical samples. Depleting Tregs with anti-CTLA-4 antibody rescued the anti-tumor immune response and led to enhanced tumor control in combination with anti-PD-1 and KRAS-G12C inhibitor. We therefore propose use of KRAS-G12C inhibitor in combination with Treg depletion as a therapeutic opportunity that increases anti-tumoral immune responses and initiates tumor regression.

Cancer Biology

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is: in the lung cancer model, why KRAS - G12C inhibitors (such as MRTX1257) combined with immune checkpoint blockade therapy (such as anti - PD - 1) fail to effectively enhance the anti - tumor immune response. Through spatial proteomics analysis, the researchers found that regulatory T cells (Tregs) may locally suppress the immune response induced by KRAS - G12C inhibitors, thus leading to resistance to treatment. Therefore, the paper explores how to enhance the synergy between KRAS - G12C inhibitors and immune checkpoint blockade therapy by eliminating Tregs, in order to improve the anti - tumor immune response and promote tumor regression.

Specifically, the paper explored the spatial patterns in the lung cancer microenvironment through Multiplex Imaging Mass Cytometry (IMC) and identified a "community" containing local T - cell activation characteristics, in which CD4+ and CD8+ T cells and dendritic cells gather together. Although KRAS - G12C inhibitors lead to an increase in PD - 1 expression on T cells, an increase in CXCL9 expression on dendritic cells, and an increase in the proliferation and potential cytotoxicity of CD8+ T cells, indicating an effector response, the researchers observed a high proportion of Tregs in this "community", and these Tregs frequently contact effector T cells, suggesting that Tregs may locally attenuate the anti - tumor immune response induced by KRAS - G12C inhibitors.

To verify this hypothesis, the researchers depleted Tregs using anti - CTLA - 4 antibodies in in - vivo experiments, and as a result, the anti - tumor immune response was restored and the tumor control effect was significantly improved when combined with anti - PD - 1 and KRAS - G12C inhibitors. This indicates that combining KRAS - G12C inhibitors with Treg depletion may be a new treatment strategy for enhancing the anti - tumor immune response.